Meropenem and piperacillin/tazobactam optimised dosing regimens for critically ill patients receiving renal replacement therapy
Meropenem and piperacillin/tazobactam optimised dosing regimens for critically ill patients receiving renal replacement therapy
Purpose
Optimal dosing of meropenem and piperacillin/tazobactam in critically ill patients receiving renal replacement therapy (RRT) is uncertain due to variable pharmacokinetics. We aimed to develop generalisable optimised dosing recommendations for these antibiotics.
Methods
Prospective, multinational pharmacokinetic study including patients requiring various forms of RRT. Independent population PK models were developed, externally validated and applied to perform Monte Carlo dosing simulations using Monolix and Simulx. We calculated the probability that these dosing regimens achieved standard and high therapeutic unbound antibiotic concentrations over 100% of the dosing interval for the treatment of Enterobacterales and Pseudomonas aeruginosa.
Results
We enrolled 300 patients from 22 intensive care units across 12 countries receiving continuous veno-venous haemodialysis (13.0%), haemofiltration (23.3%), haemodiafiltration (48.4%) or sustained low-efficiency dialysis (15.3%). Models were developed using data from 234 patients (8322 samples) and validated with 66 additional patients (560 samples). Predictive performance was high, with mean prediction errors of − 5.2% for meropenem and − 16.9% for piperacillin. Dosing simulations showed that meropenem and piperacillin/tazobactam dosing requirements were dependent on urine output and RRT intensity and duration (p < 0.05). In all scenarios, extended/continuous infusions led to a better achievement of effective concentrations with lower daily doses compared to short infusion. Dosing nomograms were developed to inform dosing for different RRT settings, urine outputs, and target concentrations.
Conclusion
RRT intensity and duration and urine output determine meropenem and piperacillin/tazobactam dosing requirements in critically ill patients receiving RRT. Extended/continuous infusions facilitate the attainment of effective concentrations.
1628–1640
Mckenzie, Cathrine
13ad9cca-fa4f-451b-a3f4-5c83d1ef3b8c
Roberts, Jason
3ae8e0f2-3f39-4f32-89c7-cae1c93f4e20
lipmann, jeffrey
a913a27a-ebf0-4fc2-91aa-8bfa9ada0546
Ulldemolins, Marta
1c4c8a34-61a7-4017-a949-ceab498404bf
Liu, Xin
a47de05e-a1bb-41a5-934f-263cb662365a
Baptista, João P.
d34b399d-58ba-47be-a9ce-39d0a29b8e98
Bilgrami, Irma
38a4a626-1041-400a-825d-54b8c7ffedb3
Boidin, Clement
455b3ab5-32b6-40d0-89a9-3de5bed394d1
Brinkmann, Alexander
9f071a81-4acb-4ec2-a0d9-e33b92088761
Castro, Pedro
d60d3b4f-13c8-4b30-a126-0b6b0d5120ad
13 August 2025
Mckenzie, Cathrine
13ad9cca-fa4f-451b-a3f4-5c83d1ef3b8c
Roberts, Jason
3ae8e0f2-3f39-4f32-89c7-cae1c93f4e20
lipmann, jeffrey
a913a27a-ebf0-4fc2-91aa-8bfa9ada0546
Ulldemolins, Marta
1c4c8a34-61a7-4017-a949-ceab498404bf
Liu, Xin
a47de05e-a1bb-41a5-934f-263cb662365a
Baptista, João P.
d34b399d-58ba-47be-a9ce-39d0a29b8e98
Bilgrami, Irma
38a4a626-1041-400a-825d-54b8c7ffedb3
Boidin, Clement
455b3ab5-32b6-40d0-89a9-3de5bed394d1
Brinkmann, Alexander
9f071a81-4acb-4ec2-a0d9-e33b92088761
Castro, Pedro
d60d3b4f-13c8-4b30-a126-0b6b0d5120ad
Mckenzie, Cathrine, Roberts, Jason, lipmann, jeffrey, Ulldemolins, Marta, Liu, Xin, Baptista, João P., Bilgrami, Irma, Boidin, Clement, Brinkmann, Alexander and Castro, Pedro
(2025)
Meropenem and piperacillin/tazobactam optimised dosing regimens for critically ill patients receiving renal replacement therapy.
Intensive Care Medicine, 51, .
Abstract
Purpose
Optimal dosing of meropenem and piperacillin/tazobactam in critically ill patients receiving renal replacement therapy (RRT) is uncertain due to variable pharmacokinetics. We aimed to develop generalisable optimised dosing recommendations for these antibiotics.
Methods
Prospective, multinational pharmacokinetic study including patients requiring various forms of RRT. Independent population PK models were developed, externally validated and applied to perform Monte Carlo dosing simulations using Monolix and Simulx. We calculated the probability that these dosing regimens achieved standard and high therapeutic unbound antibiotic concentrations over 100% of the dosing interval for the treatment of Enterobacterales and Pseudomonas aeruginosa.
Results
We enrolled 300 patients from 22 intensive care units across 12 countries receiving continuous veno-venous haemodialysis (13.0%), haemofiltration (23.3%), haemodiafiltration (48.4%) or sustained low-efficiency dialysis (15.3%). Models were developed using data from 234 patients (8322 samples) and validated with 66 additional patients (560 samples). Predictive performance was high, with mean prediction errors of − 5.2% for meropenem and − 16.9% for piperacillin. Dosing simulations showed that meropenem and piperacillin/tazobactam dosing requirements were dependent on urine output and RRT intensity and duration (p < 0.05). In all scenarios, extended/continuous infusions led to a better achievement of effective concentrations with lower daily doses compared to short infusion. Dosing nomograms were developed to inform dosing for different RRT settings, urine outputs, and target concentrations.
Conclusion
RRT intensity and duration and urine output determine meropenem and piperacillin/tazobactam dosing requirements in critically ill patients receiving RRT. Extended/continuous infusions facilitate the attainment of effective concentrations.
Text
Meropenem_and_piperacillintazobactam_optimised_dos
- Version of Record
Text
Meropenem_and_piperacillintazobactam_optimised_dos
- Version of Record
More information
Accepted/In Press date: 25 July 2025
Published date: 13 August 2025
Identifiers
Local EPrints ID: 506345
URI: http://eprints.soton.ac.uk/id/eprint/506345
ISSN: 0342-4642
PURE UUID: cf78627e-24f3-411c-b8f6-d373f636d494
Catalogue record
Date deposited: 04 Nov 2025 18:14
Last modified: 05 Nov 2025 03:18
Export record
Contributors
Author:
Cathrine Mckenzie
Author:
Jason Roberts
Author:
jeffrey lipmann
Author:
Marta Ulldemolins
Author:
Xin Liu
Author:
João P. Baptista
Author:
Irma Bilgrami
Author:
Clement Boidin
Author:
Alexander Brinkmann
Author:
Pedro Castro
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics